产品目录
| 编号 | 化学名称 | Cas号 | 纯度 | 化学结构 |
|---|---|---|---|---|
| 2091204 | 2,4-二甲基-5-羟基嘧啶 | 412003-95-3 | ≧96.0% | _412003-95-3.png) |
| 我们可以生产公斤级的2,4-二甲基-5-羟基嘧啶 （CAS 412003-95-3）。 | ||||
| 24101 | Crelosidenib | 2230263-60-0 | ≧98.0% |  |
| Crelosidenib （ [LY3410738）是一种有效的选择性的具有口服活性的突变 | ||||
| 25076 | HC-7366 | 2803470-63-3 | ≧98.0% |  |
| HC-7366 is a potent and selective activator of the general control nonderepressible 2 | ||||
| 41788 | CB-6644 | 2316817-88-4 | 96.33% |  |
| CB-6644 acts as a noncompetitive ATPase inhibitor. Additionally, it can inhibit RUVBL | ||||
| 21075 | 1-cyanocyclohexyl 4-methylbenzenesulfonate | 90775-01-2 | ≧98.0% |  |
| 1-cyanocyclohexyl 4-methylbenzenesulfonate (CAS 90775-01-2 ) 是有机合成反应中 | ||||
| 25079 | Sevabertinib ( 别名：BAY-2927088 ) | 2521285-05-0 | ≧98.0% |  |
| Sevabertinib ( BAY-2927088 )是一种口服非共价酪氨酸激酶受体抑制剂（ | ||||
| 171653 | 4-溴-2-氰基-6-甲氧基吡啶 | 886372-53-8 | ≧95.0% |  |
| 4-溴-2-氰基-6-甲氧基吡啶, CAS 886372-53-8 | ||||
| 20633 | Tersolisib ( STX-478 ) | 2883540-92-7 | ≧98.0% |  |
| Tersolisib ( STX-478 ) 是第二代突变体选择性口服 PI3Ka 小分子变构抑制 | ||||
| 25148 | Atebimetinib | 2669009-92-9 | ≧98.0% |  |
| 阿替美替尼（IMM-1-104）是一种口服的小分子MEK1和MEK2激酶变构抑制 | ||||
| 21253 | 4-吲哚硼酸频那醇酯 | 388116-27-6 | ≧95.0% |  |
| indole-4-boronic acid pinacol ester, CAS 388116-27-6, is an importantintermeidate. | ||||
| 24084 | Iclepertin (BI-425809) | 1421936-85-7 | ≧98.0% | _1421936-85-7.png) |
| Iclepertin（BI-425809）是一种口服的GlyT-1小分子抑制剂，用于治疗与 | ||||
| 25075 | LLL12 | 1260247-42-4 | ≧97.0% |  |
| LLL12是一种强效的STAT3抑制剂。LLL12在小鼠异种移植物模型中显示出 | ||||